Healthcare Services

Genomic Urine Testing Market Revenue Growth Expected to Reach $1.79 Billion by 2030 with 12.2% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Genomic Urine Testing Market In 2026 And What Value Is Projected For 2030?

The genomic urine testing market has experienced rapid expansion in recent years. It is projected to increase from $1.01 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. The growth observed in the historical period stems from advances in molecular diagnostics, the demand for non-invasive testing, early biomarker research, the adoption of genomic assays by laboratories, and the overall growth in oncology diagnostics.

The genomic urine testing market is anticipated to exhibit rapid expansion over the next few years, with its valuation expected to reach $1.8 billion in 2030, maintaining a compound annual growth rate (CAGR) of 12.2%. The projected growth within this period stems from its integration with routine health screening, an expansion into infectious disease detection, technological enhancements in sensitivity, the demand for personalized monitoring, and ongoing clinical validation studies. Significant trends during the forecast period include the increasing adoption of non-invasive diagnostic testing, a rising utilization of genomic biomarkers for disease detection, a growing need for tools for early cancer screening, the broadening of personalized diagnostic approaches, and increased research into urinary genomic profiling.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

What Major Drivers Are Influencing Demand In The Genomic Urine Testing Market?

The increasing prevalence of chronic kidney disease (CKD) is projected to drive the expansion of the genomic urine testing market. CKD is defined as a state where kidneys are compromised and can no longer effectively purify blood, leading to the accumulation of waste and fluids within the body. The escalating burden of CKD is linked to the rising occurrence of diabetes, as elevated blood sugar levels harm kidney blood vessels, thereby hindering their waste-filtering capacity. Genomic urine testing assists in CKD management by facilitating the early identification of genetic indicators, which allows for timely interventions and tailored treatment plans. It contributes to improved patient outcomes by enabling more accurate oversight and decelerating disease progression. For instance, in November 2025, according to The American Journal of Managed Care, a US-based peer-reviewed medical publication, 788 million adults aged 20 and older were living with CKD in 2023. Therefore, the growing burden of chronic kidney disease is a significant impetus for the growth of the genomic urine testing market.

What Are The Key Segments Of The Genomic Urine Testing Market?

The genomic urine testing market covered in this report is segmented –

1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

Which Upcoming Trends Are Expected To Influence The Genomic Urine Testing Market?

Leading companies active in the genomic urine testing market are concentrating on developing advanced solutions, including next-generation sequencing, to improve the precision, responsiveness, and prompt identification features of non-invasive diagnostic tests for numerous conditions. Next-generation sequencing (NGS) is a sophisticated DNA sequencing technology that enables the swift, accurate, and extensive examination of genetic material by concurrently sequencing millions of deoxyribonucleic acid (DNA) fragments. For example, in May 2023, Convergent Genomics Inc., a US-based biotechnology firm, unveiled the genomic urine test UroAmp. This test employs next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes connected to bladder cancer, facilitating early detection up to 12 years before clinical symptoms emerge. It offers detailed genetic insights to direct diagnosis, inform treatment strategies, and monitor for recurrence, providing superior accuracy compared to conventional approaches like cytology and cystoscopy.

Who Are The Leading Companies Operating In The Genomic Urine Testing Market?

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

Read the full genomic urine testing market report here:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Genomic Urine Testing Market?

North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Genomic Urine Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2026, By The Business Research Company

Genomics Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Genomics Personalized Health Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-personalized-health-global-market-report

Bioinformatics Global Market Report

https://www.thebusinessresearchcompany.com/report/bioinformatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795